Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Smith

Internal Medicine Pottstown, PA Doctor of Osteopathy

NPI 1598729055 CMS profile 117855

545 E High St, Pottstown, PA 19464

Open in the dashboard

General payments

$6,347

400 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Smith of Pottstown, PA is reported in the CMS Open Payments database as having received $6,347 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38 2
2024 General $67 4
2023 General $1,409 75
2022 General $1,344 76
2021 General $1,060 83
2020 General $894 54
2019 General $1,534 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Smith
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Smith were reported at $38. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Smith Internal Medicine median Middle half National median
2019 $1,534 $159 $48–$570 $163
2020 $894 $119 $33–$402 $114
2021 $1,060 $135 $37–$521 $132
2022 $1,344 $141 $42–$496 $149
2023 $1,409 $149 $45–$519 $160
2024 $67 $154 $47–$537 $164
2025 $38 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $990 61 payments
  2. Pfizer Inc. $730 61 payments
  3. Novo Nordisk Inc $522 31 payments
  4. Lilly USA, LLC $467 32 payments
  5. AstraZeneca Pharmaceuticals LP $376 25 payments
  6. GlaxoSmithKline, LLC. $330 16 payments
  7. Amgen Inc. $296 17 payments
  8. W. L. Gore & Associates, Inc. $275 13 payments
  9. Merck Sharp & Dohme Corporation $251 16 payments
  10. Amarin Pharma Inc. $244 17 payments
  11. Other $1,865 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,312 396 payments
  2. Education $34 4 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR $420 27 payments
  2. ELIQUIS $323 33 payments
  3. CARDIOFORM Septal Occluder $275 13 payments
  4. UBRELVY $250 16 payments
  5. TRULICITY $227 17 payments
  6. FARXIGA $215 14 payments
  7. Repatha $211 12 payments
  8. STEGLATRO $185 11 payments
  9. BELSOMRA $175 10 payments
  10. Vascepa $174 12 payments
  11. Other $5,690 361 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

934

Median for Internal Medicine: 777

Drug cost

$40,129

Median for Internal Medicine: $73,373

Branded share of claims

4.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 15 $19,232
Eliquis Apixaban Brand 12 $12,347
Atorvastatin Calcium Generic 117 $1,052
Pantoprazole Sodium Generic 39 $786
Levothyroxine Sodium Generic 42 $652
Metoprolol Succinate Generic 32 $634
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 11 $487
Losartan Potassium Generic 46 $482
Amlodipine Besylate Generic 55 $393
Simvastatin Generic 38 $382

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $39
$39 — —
UBRELVY
  • AbbVie, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record